RETINAL DYSTROPHY
Clinical trials for RETINAL DYSTROPHY explained in plain language.
Never miss a new study
Get alerted when new RETINAL DYSTROPHY trials appear
Sign up with your email to follow new studies for RETINAL DYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a common diabetes drug protect eyesight in stargardt disease?
Disease control OngoingThis study tests whether metformin, a widely used diabetes drug, can safely slow vision loss in people with ABCA4 retinopathy (Stargardt disease). Fifty-five participants aged 12 and older will take metformin by mouth for 24 months, with regular eye exams to track changes. The go…
Matched conditions: RETINAL DYSTROPHY
Phase: PHASE1, PHASE2 • Sponsor: National Eye Institute (NEI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Custom drug targets rare blindness in One-Patient trial
Disease control OngoingThis study tests a custom-made drug called an antisense oligonucleotide, designed specifically for one person with retinal dystrophy caused by a PRPH2 gene mutation. The drug aims to correct the genetic error and potentially slow vision loss. The trial involves only one participa…
Matched conditions: RETINAL DYSTROPHY
Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 26, 2026 17:51 UTC